Castle Biosciences is a biomarker-based cancer diagnostics company focused on under-served, orphan diseases. Our first product, DecisionDx-GBM, is a proprietary molecular diagnostic assay from M.D. Anderson that prospectively stratifies patient responses to first line treatment for glioblastoma, the most prevalent form of primary brain cancer. Validation is being completed in Dec ‘08 and the product will be available in 1Q09.
Our second product, DecisionDx-LEA, provides similar treatment decision benefits for its targeted cancer and we expect to launch it during 2H09. We are on track to achieve positive cash flow by year end.